Randomized open trial for comparison of proton pump inhibitors in triple therapy for <i>Helicobacter pylori</i> infection in relation to <i>CYP2C19</i> genotype

Abstract

The overall cure rate of 1-week triple therapy for H. pylori eradication was not significantly different between regimens with omeprazole, lansoprazole or rabeprazole, but the impact of CYP2C19 genetic polymorphism on the cure rate appeared to differ between these PPI.